Abbott Rolls Out Next-Gen NeuroSphere myPath Digital Health App

Abbott today launched an upgraded version of the NeuroSphere myPath digital health app to more closely track patients trialing Abbott neurostimulation devices to treat chronic pain. The app is available for both Android and Apple devices and provides a shared view of patient-reported outcome measures which trying a spinal cord stimulation (SCS) or dorsal root ganglion (DRG) device.
 
“With NeuroSphere myPath, I am able to connect with my patients virtually because I can hone in on the precise location where they are experiencing pain and understand whether they are receiving relief,” Pankaj Mehta, M.D., clinical president and chief medical officer at Pain Specialists of America told the press. “Because the app is designed to provide a virtual environment in which I can connect with every patient and see where they are in the process, I can track how each person is doing, share critical data insights with my colleagues and help them take the next step in their pain-relief journey.”
 
NeuroSphere myPath offers a series of surveys taken virtually at baseline and during the trial period. Questions are asked about pain intensity, relief, changes to physical function, and overall mood/well-being throughout the trial journey. Doctors receive a comprehensive report at the end of the trial.
 
Clinicians can also prescribe new treatment settings remotely using a programmer app and remote care connection.
 
“Our continued advancement of the NeuroSphere myPath app is part of Abbott’s commitment to developing new connected health technology that has the potential to bridge the gap between people and their doctors,” Pedro Malha, vice president, Neuromodulation, Abbott. “Both the myPath digital app and our NeuroSphere Virtual Clinic allow us to deliver a more personalized and proactive approach to how advanced diseases are managed that are changing how people access healthcare around the world.”